硫酸高乌甲素对人宫颈癌Hela细胞增殖、周期与凋亡的影响  

Effects of Lappaconitine Sulfate on Proliferation,Cycle and Apoptosis of Human Cerical Neoplasm Hela Cells

作　　者：马君义[1,2] 陈香玲[1] 后春静 朱建朝 韩小芬[1] 张继[1,2] 郭红云[3] 

机构地区：[1]西北师范大学生命科学学院,兰州730070 [2]甘肃特色植物有效成分制品工程技术研究中心,兰州730070 [3]甘肃省医学科学研究院,兰州730050

出　　处：《中国药学杂志》2017年第12期1038-1043,共6页Chinese Pharmaceutical Journal

基　　金：甘肃省基础研究创新群体计划项目资助(1506RJIA116)

摘　　要：目的研究硫酸高乌甲素对人宫颈癌Hela细胞增殖、周期和凋亡的影响及其可能作用机制。方法采用细胞计数试剂盒8(CCK-8)法考察硫酸高乌甲素对Hela细胞的增殖抑制作用,并计算其半抑制浓度(IC_(50));运用流式细胞技术,采用碘化丙啶(PI)单标记法和Annexin V-FITC/PI双标记法检测硫酸高乌甲素作用后Hela细胞的细胞周期及细胞凋亡情况。结果硫酸高乌甲素对人宫颈癌Hela细胞的增殖具有抑制作用,且这种抑制作用具有明显的量效关系(r=0.990 5,P<0.01),其对Hela细胞的IC_(50)为0.421 mg·mL^(-1)。经硫酸高乌甲素作用后,Hela细胞出现了明显的G_0/G_1期阻滞,且细胞凋亡率随硫酸高乌甲素浓度的增大而逐渐升高。结论硫酸高乌甲素能抑制Hela细胞的生长,可改变细胞周期分布并诱导其凋亡。OBJECTIVE To observe the effects of lappaconitine sulfate on proliferation, cycle and apoptosis of human cerical ne- oplasm Hela cells and its possible mechanism. METHODS Cell Counting Kit-8 （CCK-8） was adopted to observe the inhibitory effects of lappaconitine sulfate on the proliferation of Hela ceils and calculated its half maximal inhibitory concentration （ IC50 ）. The technology of flow cytometry, propidium iodide （PI） single stained method and Annexin-V-FITC/PI double stained method were em- ployed to measure the cell cycle and apoptosis of Hela cells after lappaconitine sulfate treatment. RESULTS Lappaconitine sulfate could inhibit the proliferation of human cerical neoplasm Hela cells in vitro, and the inhibition presented obvious dose-effect relation- ship （r = 0. 990 5, P 〈 0. 01 ）. The IC50 of lappaconitine sulfate on Hela cells was 0. 421 mg · mL^-1. After dealt with lappaconitine sulfate, Hela ceils indicated remarkable cell cycle arrest at G0/G1 phase, and the apoptotic ratio was gradually increased with the con- centration of lappaconitine sulfate. CONCLUSION Lappaconitine sulfate could inhibit the growth of human cerical neoplasm Hela ceils, change the distribution of cell cycles and induce their apoptosis.

关 键 词：硫酸高乌甲素 HELA细胞 增殖 细胞周期 凋亡 宫颈癌 

分 类 号：R735.35[医药卫生—肿瘤]